Jason Rhodes, MBA

Jason Rhodes is a partner at Atlas Venture and focuses on creating and building novel therapeutics companies. He is the chairman and was the founding CEO of Generation Bio (NASDAQ: GBIO) and Dyne Therapeutics (NASDAQ: DYN). He is also on the boards of Replimune (NASDAQ: REPL), Gemini Therapeutics and Accent Therapeutics. He was the chairman and founding CEO of Disarm Therapeutics which was acquired by Eli Lilly in 2020.